Bafna Pharmaceuticals Intrinsic Value
Bafna Pharmaceuticals (BAFNAPH) median intrinsic value is ₹336.73 from 2 valuation models (range ₹269–₹337), vs current price ₹134.69 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Browse Bafna Pharmaceuticals annual reports for revenue, profit, balance sheet and cash flow data.
BAFNAPH Valuation Methods Summary — DCF, Graham Number & P/E
Bafna Pharmaceuticals intrinsic value across 2 models vs current price ₹134.69 — upside/downside and value range per method. For current market price and key ratios, visit BAFNAPH share price.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹336.73 | ₹303.06 - ₹370.40 | +150.0% | Book Value/Share: ₹255.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹269.38 | ₹242.44 - ₹296.32 | +100.0% | Revenue/Share: ₹240.00, P/S: 2.0x |
BAFNAPH Intrinsic Value vs Market Price — All Valuation Models
Bafna Pharmaceuticals fair value range ₹269–₹337 vs current market price ₹134.69 across 2 valuation models. Also explore Bafna Pharmaceuticals share price performance to track price trends across different timeframes.
BAFNAPH Intrinsic Value Analysis — Undervalued or Overvalued?
Bafna Pharmaceuticals median intrinsic value ₹336.73, current price ₹134.69 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of BAFNAPH?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Bafna Pharmaceuticals (BAFNAPH) is ₹336.73 (median value). With the current market price of ₹134.69, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹269.38 to ₹336.73, indicating ₹269.38 - ₹336.73.
Is BAFNAPH undervalued or overvalued?
Based on our multi-method analysis, Bafna Pharmaceuticals (BAFNAPH) appears to be trading below calculated value by approximately 150.0%.
BAFNAPH Financial Health — Key Ratios vs Industry Benchmarks
Bafna Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -7.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BAFNAPH Cash Flow Quality — Operating & Free Cash Flow
Bafna Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2020 | ₹-34 Cr | ₹-34 Cr | Negative Cash Flow | 3/10 |
| March 2019 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹-7 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2017 | ₹-1 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2016 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |